Navigation Links
Genesys in Medical News

Hoffa, Cherry to Speak at Community Rally Supporting Genesys Nurses

Rally To Support Local 332 Nurses Negotiating With Genesys Regional Medical Center FLINT, Mich., May 13 /PRNewswire-USNewswire/ -- Teamsters General President Jim Hoffa and Michigan Lt. Gov. John Cherry will lead a rally Wednesday, May 14, 2008, to show community support for more than 1,00...

Cell Genesys to Present at the Cowen and Company and the Lehman Brothers Healthcare Investor Conferences

SOUTH SAN FRANCISCO, Calif., March 11 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE ) today announced that Sharon E. Tetlow, senior vice president and chief financial officer of Cell Genesys, will present a company update on Tuesday, March 18 at 8:00 a.m. ET at the Cowen and Comp...

Cell Genesys Reports Fourth Quarter and Year-End 2007 Results

Conference Call Scheduled for 5:00 p.m. ET Today SOUTH SAN FRANCISCO, Calif., Feb. 28 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE ) today reported financial results for the fourth quarter and full year ended December 31, 2007. The company reported a net loss of $33....

Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer

Cell Genesys, Inc. (Nasdaq: CEGE) today announced follow-up data from a Phase 2 clinical trial of GVAX immunotherapy for pancreatic cancer which was conducted by the Johns Hopkins Sidney Kimmel Cancer Center. The trial enrolled 60 patients with operable pancreatic cancer who received GVAX after su...

Social Entrepreneur's Cup Finalists Announced

...s Today Leaders Forever and the 2008 Social Entrepreneur's Cup winner; and Jeff Tollefson, former venture capitalist and current Executive Director of genesys Works. The Social Entrepreneur's Cup finalists represent the spectrum of social needs including education, health, homelessness, and sustainable ...

Best Practices in Asia Pacific Healthcare and ICT Sectors Recognised

...ic Market Leadership F5 Networks Award in the Application Delivery Controller Market 2008 Asia Pacific Market Leadership genesys Telecommunications Award CTI Systems Market Laboratories 2008 Asia Pacific Market Leadership Aspect Software ...

Ceregene Completes Enrollment of Phase 2 Clinical Trial for Parkinson's Disease

...former subsidiary of Cell Genesys, Inc. (Nasdaq: CEGE ). The company's investors include Alta Partners, MPM Capital, Investor Growth Capital and Cell genesys as well as Hamilton BioVentures and California Technology Partners. ...

HealthShares(TM) Announces Quarterly Rebalancing of HealthShares(TM) Indexes

... 224436920.1 BioCryst Pharmaceutical Inc BCRX 216859123.5 Xoma Ltd (Bermuda) XOMA 735715935.4 Cell genesys Inc CEGE 542413535.1 Progenics Pharmaceuticals Inc PGNX 78957476.65 Gtx Inc GTXI...

New lung cancer vaccine on the anvil

...tudy is really good proof of principle that immune therapies can be translated from interesting lab findings into the treatment of patients. Cell genesys Inc., in Foster City, Calif., is developing the vaccine as a cancer treatment. The company is sponsoring phase II safety/efficacy clinical trials. ...
Genesys in Medical Technology

Cell Genesys Reports Association Between Immune Response and Patient Survival in Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer

SOUTH SAN FRANCISCO, Calif., Feb. 15 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE ) today reports the results of an analysis examining the potential association between immune responses to GVAX immunotherapy for prostate cancer and increased patient survival in a Phase 2 trial i...

Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer

SOUTH SAN FRANCISCO, Calif., April 03, 2007 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. today announced final, updated results from its second multi-center Phase 2 trial of GVAX immunotherapy for prostate cancer which evaluated escalating doses of the immunotherapy in 80 patients with metastatic ...

Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces a Broad, Patient-Specific Antibody Response

SOUTH SAN FRANCISCO, Calif., April 17, 2007 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. today reported immune response data from two previously conducted Phase 2 clinical trials of GVAX immunotherapy for prostate cancer. Evaluation of antibody responses in patients with advanced prostate cancer f...

Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer

SOUTH SAN FRANCISCO, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. today announced follow-up data from a Phase 2 clinical trial of GVAX immunotherapy for pancreatic cancer which was conducted by the Johns Hopkins Sidney Kimmel Cancer Center. The trial enrolled 60 patients with...

Interim Analysis Supports Continuation of Cell Genesys' VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer

...that study is performed according to the SPA. Cell genesys completed the modifications requested by FDA durin... Conference Call and Webcast Members of the Cell genesys management team will host a conference call today,...ence call live on the investor section of the Cell genesys website, http://www.cellgenesys.com . Alternative...

Ceregene Presents Long-term Follow-up From Phase 1 Trial of CERE-120 in Parkinson's Disease

...former subsidiary of Cell Genesys, Inc. (Nasdaq: CEGE ). The company's investors include Alta Partners, MPM Capital, Investor Growth Capital and Cell genesys as well as Hamilton BioVentures and California Technology Partners. ...

ARRIVE Registry Analysis Identifies Predictors of Stent Thrombosis in Real-World Use of Drug-Eluting Stents

... indicate that antiplatelet therapy is an important factor relating to the occurrence of stent thrombosis in DES patients," said Dr. Dobies, Director, genesys Heart Institute, Grand Blanc, Michigan. "Other significant predictors change from one to two years, suggesting differences in pathophysiology that may...
Genesys in Biological Technology

Cell Genesys to Present at the BIO CEO and Investor Conference

SOUTH SAN FRANCISCO, Calif., Feb. 4 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE ) today announced that Stephen A. Sherwin, M.D., chairman and chief executive officer of Cell Genesys, will present a company update at the BIO CEO and Investor Conference in New York, New York, on ...

Cell Genesys Announces Sale of Lentiviral Gene Delivery Technology for $12 Million

SOUTH SAN FRANCISCO, Calif., and GREENWICH, Conn., Dec. 20 /PRNewswire- FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE ) and GBP IP, LLC, an affiliate of GBP Capital, the majority shareholder in privately held Lentigen Corporation, today announced that the two companies have entered into an a...

Cell Genesys to Webcast Third Quarter 2007 Conference Call

SOUTH SAN FRANCISCO, Calif., Oct. 25 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE ), today announced that Stephen A. Sherwin, M.D., chairman and chief executive officer, and Sharon E. Tetlow, senior vice president and chief financial officer of Cell Genesys, will host a conferen...

Cell Genesys to Present at the BIO Investor Forum

SOUTH SAN FRANCISCO, Calif., Oct. 3 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE ), today announced that Robert Dow, MBChB, chief medical officer of Cell Genesys, will present a company update on Wednesday, October 10, at 10:15 a.m. PT at the BIO Investor Forum being held in San...

Cell Genesys to Present at the Bear Stearns 20th Annual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept. 4 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE ), today announced that Sharon E. Tetlow, senior vice president and chief financial officer of Cell Genesys, will present a company update at the Bear Stearns 20th Annual Healthcare Conference in N...

New Report Just Published: World Prostate Cancer Therapeutics Market Report

...Medimmune, LLC, Bristol-Myers Squibb Company, Cell genesys Inc., Dendreon Corporation, EUSA Pharma, (USA) Inc... Bavituximab in Prostate Cancer II-54 Cell genesys Reveals Data of GVAX Immunotherapy for Treatment ...or New Prostate Cancer Compound II-71 Cell genesys Forms Global Alliance with Takeda on GVAX Immu...

Mergent, Inc. Announces Quarterly Rebalancing of HealthShares(TM) Indexes

...UTICS INC. (NASDAQ: ALTH ) ARQULE INC. (NASDAQ: ARQL ) ARRAY BIOPHARMA INC. (NASDAQ: ARRY ) BIOCRYST PHARMACEUTICALS INC. (NASDAQ: BCRX ) CELL genesys INC. (NASDAQ: CEGE ) DENDREON CORP (NASDAQ: DNDN ) DYNAVAX TECHNOLOGIES CORP (NASDAQ: DVAX ) GPC BIOTECH AG-ADR (NASDAQ: GPCB ) IMMUNOGEN INC....

Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team

... served as a member of the board of directors of Monogram Biosciences (MGRM), Inc., a publicly-traded biotechnology company; and the advisory board of genesys Capital, a venture capital firm. He is the author or inventor of over 40 publications and patents. Mendlein earned his Ph.D. in physiology and biophys...

Ceregene Appoints Joao Siffert, M.D. to the Position of Chief Medical Officer

... respectively. Ceregene was launched in January 2001, and the company's investors include Alta Partners, MPM Capital, Investor Growth Capital and Cell genesys (Nasdaq: CEGE ), as well as Hamilton BioVentures and California Technology Partners. ...
Other Tags
(Date:12/25/2014)... Phoenix, AZ (PRWEB) December 25, 2014 ... comes to outstanding customer service and affordable quality regarding ... metropolitan area announces recognition in 2014 by the “Queen ... and Sons has earned an impressive reputation over the ... pricing on a wide range of contractor services for ...
(Date:12/24/2014)... 2014 Connie Casad, MD, a well-known ... advocate with 30 years of practice experience in Dallas, ... health benefits of dietary detoxification. The second study is ... excellent results from test patients who just completed a ... her interest in conducting the study, Dr. Casad said, ...
(Date:12/24/2014)... 24, 2014 Dr. Vu Ho, a ... of his practice and med-spa with the addition of ... list of cosmetic treatments and services. , “Silk Peel ... skin,” says Dr. Ho. “As a result it can ... wrinkles, sun spots, discolorations or blemishes.” , Similar to ...
(Date:12/24/2014)... The report “Stivarga (Colorectal Cancer) – Forecast ... treatment landscape, unmet needs, current pipeline and commercial opportunities ... which is used in the treatment of colon or ... also prescribed to patients who suffer from advanced gastrointestinal ... a multi-kinase inhibitor and it blocks many enzymes which ...
(Date:12/24/2014)... can be a challenge for people who suffer migraines, which ... "This is the season in which many people overindulge in ... chair of the American Migraine Foundation, said in a news ... food and beverage choices, to help reduce the risk of ... at the Mayo Clinic in Scottsdale, Ariz. , , The ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 3Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Expert Offers Tips for Preventing Holiday Migraines 2
(Date:12/17/2014)... DENVER , Dec. 16, 2014  Automation ... is this more evident than at international borders. ... secure document scanners have allowed veteran travelers to ... Automated Passport Control (APC) Kiosks at an increasing ... the globe. According to ...
(Date:12/11/2014)... SALEM, N.C. , Dec. 10, 2014  That blood ... for quite a while. Hypertension – the medical term for ... in the early 1800s, and the inflatable cuff that,s used ... That doesn,t, however, mean there,s nothing new about hypertension, its ... some long-held beliefs about the condition and the best ways ...
(Date:12/10/2014)... N.C. , Dec. 9, 2014  Wake Forest Baptist ... education building for its School of Medicine. Funding for ... larger capital campaign that will be publicly launched next ... be located in the former 60 series R.J. Reynolds ... Innovation Quarter. Construction will begin immediately with plans to ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
Other Contents